Loading...Loading...Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company’s unique business model centered around royalties and healthcare assets.The company receives royalties from GSK plc GSK for popular asthma and COPD products, including Relvar/Breo and Anoro, with combined sales of over $2 billion in 2023. “We believe their manufacturing complexity provides further protection from potential competitors,” Cantor analyst writes.Cantor projects around $1.1 billion of 5-year p ...